Add BrightSurf on Google Email

Henry VanBrocklin, PhD, FSNMMI, FSRS, receives SNMMI 2023 Paul C. Aebersold Award for Outstanding Achievement in Basic Nuclear Medicine Science

Henry VanBrocklin, a professor at the University of California, San Francisco, has been recognized for his decades-long research on novel radiopharmaceuticals and their applications in medical imaging. He is being honored with the prestigious Paul C. Aebersold Award for his contributions to nuclear medicine.

Nuclear medicine global initiative reports worldwide challenges and opportunities in theranostics education

The global nuclear medicine initiative addresses the need for standardized educational curriculums to train physicians in nuclear theranostics procedures. The report highlights the rapid evolution of theranostic radiopharmaceuticals and emphasizes the importance of continuing medical education to maintain expertise.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateJun 23, 2023

Novel imaging agent allows for earlier detection of progressive pulmonary fibrosis

A novel imaging agent has been developed to non-invasively detect pulmonary fibrosis in its early stages. The agent targets extracellular matrix fibers and has shown significant uptake in lungs with pulmonary fibrosis, matching histological results. This breakthrough could lead to earlier detection and better monitoring of the disease.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateJun 21, 2023

Innovative endoscopic imaging system can detect multiple fluorescent tracers

Researchers developed a novel endoscopic imaging system with a bioinspired sensor that can detect multiple fluorescent probes, enabling more accurate fluorescence-guided cancer surgery. The system showed improved spatial resolution and sensitivity in detecting tumors, paving the way for the adoption of multi-tracer FGS.

SourceSPIE--International Society for Optics and Photonics·JournalJournal of Biomedical Optics·DateMay 26, 2023

New framework for super-resolution ultrasound

Researchers at the Beckman Institute for Advanced Science and Technology have developed a new framework for super-resolution ultrasound using deep learning, reducing processing speeds from minutes to seconds. The new technology enables real-time blood flow visualization, overcoming challenges faced by conventional methods.

SourceBeckman Institute for Advanced Science and Technology·JournalIEEE Transactions on Medical Imaging·TypeImaging analysis·DateMay 25, 2023

Researchers overcome stem cell delivery barrier, paving the way for regenerative medicine

Scientists have developed a new method to deliver genetic information to stem cells using nanoparticles coated with a specific polymer, enabling more efficient control over cellular differentiation. This innovation has the potential to improve the efficiency and effectiveness of regenerative medicine treatments.

SourceXi'an Jiaotong-Liverpool University·JournalNano Letters·TypeExperimental study·DateMay 8, 2023

New research: FAPI PET imaging superior for diagnosing multiple types of cancer, with potential for targeted treatment

A new study has shown that FAPI PET imaging is superior to standard FDG PET in evaluating multiple types of cancer. A newly designed FAP-targeted treatment also suppressed tumor growth in several common cancers, suggesting a powerful tool for the field of clinical nuclear medicine.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateMay 2, 2023

JNM publishes appropriate use criteria for lymphoscintigraphy in sentinel node mapping and lymphedema/lipedema

The Society of Nuclear Medicine and Molecular Imaging has issued new appropriate use criteria (AUC) for lymphoscintigraphy in sentinel node mapping and lymphedema/lipedema. The AUC covers four clinical categories of cancer, including breast cancer, skin cancer, and others, and addresses pediatric considerations.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateApr 17, 2023

Blood-based biomarkers accurately predict neuroendocrine tumor response to radiopharmaceutical therapy

A blood draw can provide valuable information on the effectiveness of peptide receptor radionuclide therapy for neuroendocrine cancer patients. Blood-based biomarkers PPQ and NETest were found to predict PRRT response with 96% and 90% accuracy, respectively. The study opens possibilities for tailoring treatment to individual patients.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateApr 6, 2023

Molecular imaging offers insight into chemo-brain

A literature review published by the Society of Nuclear Medicine and Molecular Imaging reveals how nuclear medicine brain imaging can help evaluate biological changes causing chemotherapy-related cognitive impairment. The findings confirmed the impact of chemotherapy drugs on cognitive function and highlighted the utility of various SP...

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateMar 28, 2023

JNM explores potential applications for ChatGPT in nuclear medicine and molecular imaging

A new article in The Journal of Nuclear Medicine explores the potential for using ChatGPT, an artificial intelligence chatbot, in nuclear medicine and molecular imaging. The authors discuss the strengths and weaknesses of current AI bots and highlight the benefits of collaborating with AI allies to cope with increasing workloads.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateMar 27, 2023

National Comprehensive Cancer Network updates annual conference with new in-person venue, hybrid format, expert-led sessions, highlighted research perspectives, and small-group conversations

The NCCN Annual Conference will debut a new hybrid format featuring in-person events at a new venue, allowing for hallway conversations and networking opportunities. The conference will also showcase more than 100 abstract poster presentations on various oncology-related categories.

JNM publishes procedure standard/practice guideline for SSTR PET imaging of neuroendocrine tumors

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Association of Nuclear Medicine (EANM) have published a new procedure standard/practice guideline for somatostatin receptor (SSTR) PET imaging in patients with neuroendocrine tumors. The guideline focuses on improved sensitivity, lower radiation dose, and sh...

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateFeb 22, 2023

New dual-phase imaging protocol reduces costs and radiation exposure for cognitively impaired patients

A novel nuclear medicine imaging protocol, dual-phase amyloid PET, can assess both amyloid deposition and neurodegeneration with a single tracer injection, cutting costs and radiation exposure. The protocol was shown to be comparable in distinguishing patients with neurodegenerative diseases from controls.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateFeb 8, 2023

Technology development could bring Raman microscopy to the clinic

Researchers developed high-throughput Raman microscope for rapid large-area imaging hundreds of times faster than traditional approach. The new technique enables label-free molecular analysis and multiplex chemical imaging, holding promise for efficient medical diagnoses and drug development.

SourceOptica·JournalBiomedical Optics Express·DateFeb 7, 2023

E-cigarettes potentially harmful: PET imaging shows greater lung inflammation in e-cigarette users than cigarette smokers

A new study published in The Journal of Nuclear Medicine found that e-cigarette users have greater lung inflammation than cigarette smokers and non-smokers. The study used PET imaging to compare lung inflammation between e-cigarette users and cigarette smokers, revealing a unique inflammatory response in the lungs.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateJan 26, 2023

An unprecedented look at colorectal cancer

A team at Harvard Medical School has created large-scale 2D and 3D spatial maps of colorectal cancer, layering molecular information on top of histological features. The maps reveal the interconnectedness of traditional isolated structures in colorectal cancer, allowing researchers to explore differences within individual tumors.

SourceHarvard Medical School·JournalCell·DateJan 19, 2023

Nearly half of Medicare patients with non-small cell lung cancer not staged according to national guidelines: lack of adherence linked to greater mortality rates

A study found that nearly half of Medicare patients with non-small cell lung cancer do not receive the recommended FDG PET/CT imaging prior to radiation therapy, leading to decreased overall and cancer-specific survival rates. This lack of adherence is linked to greater mortality rates.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateJan 18, 2023

Nuclear medicine bone scan study identifies prevalence and outcomes of cardiac amyloidosis

A new study found that approximately three percent of all bone scan patients have markers of cardiac amyloidosis, which can lead to heart failure and increased mortality. The research highlights the importance of early diagnosis and treatment, as well as potential automated detection methods using machine-learning algorithms.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateJan 3, 2023

Novel spatial-omics technology enables investigation of diseases at their early stages

Researchers developed a new spatial-omics technology called DISCO-MS to detect early molecular changes in diseases. This approach allows for the characterization of diseased cells in intact tissues, revealing new biomarkers and therapeutic targets for conditions like Alzheimer's disease and atherosclerosis.

Novel PET agent effectively detects multiple cancers, identifies patients for targeted therapies

A new molecular imaging radiotracer, <sup> 68 </sup> Ga-PentixaFor, demonstrates high image contrast in various cancers, including hematologic malignancies and small cell lung cancer. This agent targets the C-X-C motif chemokine receptor 4 (CXCR4), which is a predictor of poor prognosis in cancer patients.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateNov 17, 2022

PET/MRI machine learning model can eliminate sentinel lymph node biopsy in majority of breast cancer patients

A new study published in The Journal of Nuclear Medicine found that a PET/MRI machine learning model can reliably distinguish between patients with and without lymph node metastases. This breakthrough technology has the potential to eliminate sentinel lymph node biopsy, a common procedure for breast cancer treatment.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateNov 10, 2022

Charting the human brain with new tools

Researchers are developing a comprehensive cell atlas for the human brain, which would cover billions of cells and provide a holistic description of its properties. Advanced visualization techniques have been developed to catalog brain regions and cell types, enabling better resolution and accuracy in studying neural circuits.

Seeing clearly into a new realm – researchers prototype a new generation of quantum microscopy

A team of researchers has developed a prototype of a quantum microscope that can see electric currents, detect fluctuating magnetic fields, and even see single molecules on a surface. The microscope uses atomic impurities and van der Waals materials to achieve high resolution sensitivity and simultaneous imaging of magnetic fields and ...

SourceUniversity of Technology Sydney·JournalNature Physics·TypeExperimental study·DateNov 7, 2022

Light-driven molecular motors light up

Scientists have successfully created two types of light-driven molecular motors that can both rotate and fluoresce in the same molecule. This achievement demonstrates that these motors can be designed to control various functions using light energy, paving the way for potential applications in biomedical imaging and cellular processes.

SourceUniversity of Groningen·JournalScience Advances·TypeExperimental study·DateNov 4, 2022

Head and neck cancer: Markers to facilitate better treatment in the future

A study published in European Journal of Nuclear Medicine and Molecular Imaging identified specific genetic markers associated with high risk of head and neck cancer. The research used DNA sequencing, artificial intelligence, and positron emission tomography to analyze cellular characteristics of tumors. These markers can facilitate mo...

SourceMedical University of Vienna·JournalEuropean Journal of Nuclear Medicine and Molecular Imaging·DateOct 25, 2022

Novel PET imaging agent detects earliest signs of Alzheimer’s disease

A new radiotracer, 18F-SMBT-1, detects overexpressed monoamine oxidase-B in cognitively unimpaired individuals with high beta amyloid levels, a key early sign of Alzheimer's disease. The agent shows increased binding to reactive astrocytes, suggesting its potential as a surrogate marker for detecting Alzheimer's disease.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateOct 19, 2022

Zinc enhances albumin’s protective role against Parkinson's disease

Researchers have discovered that zinc ions tune the ability of human serum albumin to prevent α-synuclein aggregation, a process linked to Parkinson's disease. Zinc binding alters HSA's chaperone function, blunting fibril formation and slowing down protein deposition that can lead to neurodegeneration.

SourceKing Abdullah University of Science & Technology (KAUST)·JournalInternational Journal of Biological Macromolecules·DateOct 16, 2022

Pitt-developed genetic test for pancreatic cancer outperforms current guidelines

A new genetic test called PancreaSeq accurately classifies pancreatic cysts as potentially cancerous or benign, improving the accuracy of diagnoses compared to current guidelines. The test distinguishes between different types of cysts with higher accuracy than traditional forms of surveillance and current pancreatic cyst guidelines.

SourceUniversity of Pittsburgh·JournalGastroenterology·TypeObservational study·DateOct 5, 2022